Drugs / ATG-018
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05338346 | Jul 2022 → Jan 2024 | cancer, hematopoietic and lymphoid cell neoplasm | Antengene Discovery Limited | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-08-25 | Antengene Corporation | Results Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline antengene.com ↗
7 patients are with stable disease out of 12 efficacy evaluable patients at low dose levels. |
| 2022-11-11 | Antengene Corporation | Results Antengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting antengene.com ↗
Through these studies, results showed that ATG-018 inhibited the expression of a set of chemokine genes (CCL2, CCL3/1 and CCL4) and that they could be detected in unmanipulated blood samples. |
| 2022-06-07 | Antengene Corporation | Regulatory Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018 antengene.com ↗ |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-08-25 | Antengene Corporation | Antengene Announces Interim Financial Results for 2023 with New Clinical Data Highlighting the Growing Value of Its Pipeline antengene.com ↗ |
| 2022-11-11 | Antengene Corporation | Antengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting antengene.com ↗ |
| 2022-08-16 | Antengene Corporation | Antengene Announces First Patient Dosed of Small Molecule ATR ATG-018 for the Treatment of Patients with Advanced Solid Tumors and Hematologic Malignancies in Australia antengene.com ↗ |
| 2022-06-07 | Antengene Corporation | Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018 antengene.com ↗ |
| 2022-04-27 | Antengene Corporation | Antengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018 antengene.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATG-018 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05338346 ↗ |
| Action | Inhibit | “ATG-018 (ATR inhibitor)” NCT05338346 ↗ |
| Route | Oral | “ATG-018 administered orally” NCT05338346 ↗ |